Vical Reports First Quarter 2017 Financial Results
May 15 2017 - 6:30AM
Vical Incorporated (Nasdaq:VICL) today reported financial results
for the three months ended March 31, 2017. Net loss for the first
quarter of 2017 was $2.8 million, or $0.25 per share, compared with
a net loss of $2.4 million, or $0.26 per share, for the first
quarter of 2016. Revenues for the first quarter of 2017 were $3.2
million, compared with revenues of $4.6 million for the first
quarter of 2016, reflecting revenues from Astellas Pharma Inc. for
manufacturing services performed under our ASP0113 collaborative
agreements.
Vical had cash and investments of $39.2 million
at March 31, 2017. The Company’s net cash burn for the first
quarter of 2017 was $1.8 million, which was consistent with the
Company’s full year guidance of between $8 million and $11
million.
Program updates include:
ASP0113 CMV Therapeutic
Vaccine
- The multinational Phase 3 registration trial in HCT recipients
completed enrollment in September 2016 with a total of 515
subjects. Dosing in the trial was completed in April 2017 and the
follow-up period is expected to be finished in September 2017. The
primary endpoint of the trial is a composite of overall mortality
and CMV end organ disease which will be assessed one year after
transplantation. Astellas expects top-line data to be available in
the first quarter of 2018. Vical and Astellas continue to make
progress towards a potential BLA filing in 2018.
VCL-HB01 HSV-2 Therapeutic
Vaccine
- Recruitment into the Phase 2 trial of the VCL-HB01 HSV-2
therapeutic vaccine has been completed with a total of 261 subjects
enrolled at 15 U.S. clinical sites. VCL-HB01 is formulated
with Vaxfectin® and encodes two full-length HSV-2 antigens gD and
UL46, and is designed to reduce recurrences in patients with
symptomatic genital HSV-2 infection. Healthy adult subjects, 18 to
50 years of age, have been randomized 2:1 to receive either vaccine
or placebo to evaluate the efficacy and safety of the vaccine. The
primary endpoint of the study is annualized lesion recurrence rate
which is a clinically meaningful endpoint for both patients and
treating physicians as it provides important information on the
number of recurrences over time in this chronic disease setting.
Vical expects to deliver top-line results during the second quarter
of 2018.
VL-2397 Antifungal
- The VL-2397 development program will be featured in four poster
presentations and an oral presentation at the June ASM Microbe
meeting in New Orleans.
- Vical has completed its first-in-human Phase 1 trial of its
novel antifungal, VL-2397. The randomized, double-blind,
placebo-controlled trial was designed to evaluate safety,
tolerability and pharmacokinetics of single and multiple ascending
doses of intravenous VL-2397 in 96 healthy volunteers. Results
point to a favorable safety and pharmacokinetic profile for
VL-2397. The data will be highlighted in one of the four poster
presentations at ASM Microbe.
- Vical plans to conduct a Phase 2 efficacy study to evaluate
VL-2397 for the treatment of invasive aspergillosis and is working
with clinical experts and the FDA towards this objective. The FDA
has granted Vical Qualified Infectious Disease Product (QIDP),
Orphan Drug and Fast Track designations to VL-2397 for the
treatment of invasive aspergillosis. Under the QIDP designation
Vical has been able to interact intensively with the FDA on the
design of the Phase 2 trial and in exploring an expedited
development pathway for VL‑2397.
- Invasive aspergillosis represents a major unmet medical need
given the high mortality rate in immunocompromised patients,
despite availability of current antifungal therapies.
Vical will conduct a conference call and webcast
today, May 15, at noon Eastern Time, to discuss the Company’s
financial results and program updates with invited participants.
The call and webcast are open on a listen-only basis to any
interested parties. To listen to the conference call, dial in
approximately ten minutes before the scheduled call to
(719)325-2361 (preferred), or (888)466-4462 (toll-free), and
reference confirmation code 9047479. A replay of the call will be
available for 48 hours beginning about two hours after the call. To
listen to the replay, dial (719)457-0820 (preferred) or
(888)203-1112 (toll-free) and enter replay passcode 9047479. The
call will also be available live and archived through the events
page at www.vical.com. For further information, contact Vical’s
Investor Relations department by phone at (858)646-1127 or by
e-mail at ir@vical.com.
About Vical
Vical develops biopharmaceutical products for
the prevention and treatment of chronic or life-threatening
infectious diseases, based on its patented DNA delivery
technologies and other therapeutic approaches. Additional
information on Vical is available at www.vical.com.
Forward-Looking Statements
This press release contains forward-looking
statements subject to risks and uncertainties that could cause
actual results to differ materially from those projected.
Forward-looking statements include net cash use guidance, as well
as anticipated developments in independent and collaborative
programs, including the plans, timing of initiation, enrollment and
announcement of data for clinical trials. Risks and uncertainties
include whether Vical or others will continue development of
ASP0113, Vical’s HSV-2 vaccine, VL-2397 or any other independent or
collaborative programs; whether Vical will achieve levels of
revenues and control expenses to meet its financial projections;
whether enrollment in on-going trials will continue at current
rates; whether Vical or its collaboration partners will be able to
obtain regulatory allowances or guidance necessary to proceed with
proposed clinical trials or implement anticipated clinical trial
designs; whether on-going or planned clinical trials will be
initiated or completed on the timelines Vical currently expects,
whether any product candidates will be shown to be safe and
efficacious in clinical trials; whether Vical is able to continue
its collaborative arrangements or enter into new ones; whether
Vical will have access to sufficient capital to fund its planned
development activities; whether Vical or its collaborative partners
will seek or gain approval to market any product candidates; and
additional risks set forth in the Company's filings with the
Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
VICAL
INCORPORATED |
|
Selected Condensed Financial Information
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Statements of Operations |
|
|
March 31, |
|
(in
thousands, except per share amounts) |
|
|
2017 |
|
|
2016 |
|
|
Revenues: |
|
|
|
|
|
|
|
|
Contract revenue |
|
|
$ |
2,901 |
|
|
$ |
4,088 |
|
|
License and royalty revenue |
|
|
|
304 |
|
|
|
516 |
|
|
Total
revenues |
|
|
|
3,205 |
|
|
|
4,604 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
|
3,300 |
|
|
|
2,478 |
|
|
Manufacturing and production |
|
|
|
1,309 |
|
|
|
2,846 |
|
|
General and administrative |
|
|
|
1,509 |
|
|
|
1,790 |
|
|
Total
operating expenses |
|
|
|
6,118 |
|
|
|
7,114 |
|
|
Loss from operations |
|
|
|
(2,913 |
) |
|
|
(2,510 |
) |
|
Net investment and other income |
|
|
|
89 |
|
|
|
87 |
|
|
Net
loss |
|
|
$ |
(2,824 |
) |
|
$ |
(2,423 |
) |
|
Basic
and diluted net loss per share |
|
|
$ |
(0.25 |
) |
|
$ |
(0.26 |
) |
|
Weighted
average shares used in computing |
|
|
|
|
|
|
|
|
basic and diluted net loss per share |
|
|
11,101 |
|
|
9,217 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheets |
|
|
|
|
|
|
March 31, |
|
December 31, |
|
(in
thousands) |
|
|
|
|
|
|
2017 |
|
|
2016 |
|
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents, and marketable |
|
|
|
|
|
|
|
|
|
|
|
|
securities, including restricted |
|
|
|
|
|
|
$ |
37,091 |
|
|
$ |
38,932 |
|
|
Other current assets |
|
|
|
|
|
|
|
10,106 |
|
|
|
8,935 |
|
|
Total
current assets |
|
|
|
|
|
|
|
47,197 |
|
|
|
47,867 |
|
|
Long-term investments |
|
|
|
|
|
|
|
2,108 |
|
|
|
2,046 |
|
|
Property
and equipment, net |
|
|
|
|
|
|
|
964 |
|
|
|
1,173 |
|
|
Other
assets |
|
|
|
|
|
|
|
1,172 |
|
|
|
1,198 |
|
|
Total
assets |
|
|
|
|
|
|
$ |
51,441 |
|
|
$ |
52,284 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders' equity: |
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
$ |
8,855 |
|
|
$ |
7,145 |
|
|
Stockholders' equity |
|
|
|
|
|
|
|
42,586 |
|
|
|
45,139 |
|
|
Total
liabilities and stockholders' equity |
|
|
|
|
|
|
$ |
51,441 |
|
|
$ |
52,284 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contacts:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
Anthony Ramos
Vice President and Chief Accounting Officer
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024